Company Profile
415 Capital is a specialized venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. The firm focuses on addressing large unmet patient needs within chronic diseases, with a particular emphasis on cardio and neurovascular disorders. Their mission is to improve patient outcomes and quality of life while simultaneously reducing long-term healthcare costs.
The firm's team boasts over 25 to 30 years of experience in the MedTech sector, providing capital, expertise, and market access to exceptional entrepreneurs. 415 Capital's investment strategy targets medical technologies at clinical through commercial stages, typically deploying €5-15 million per company. They have a strong track record, having funded over 50 medical technology companies, achieved more than 25 realized exits through trade-sales and IPOs, and currently manage over 25 active investments.
415 Capital's investment focus includes areas such as Structural Heart Disease, Heart Failure, Aortic & Peripheral Vascular Disease, Neurovascular Disease / Stroke, Hypertension, Electrophysiology, Neuromodulation for Chronic Diseases, Medical Imaging, Medical Robotics, and Patient Monitoring. Geographically, the firm invests across Europe, Israel, and North America, leveraging close collaborations with leading physicians and healthcare providers to support portfolio companies from R&D through commercialization.
The firm's diverse team combines backgrounds in investing, entrepreneurship, biomedical engineering, regulatory affairs, quality control, medicine, and medical device commercialization. This expertise is complemented by a dedicated clinical team of physicians and specialists who provide proprietary insights into daily clinical practice, ensuring a deep understanding of medical innovation and patient care.
News & Signals (0)
No linked news activity found for this company.